Bonus BioGroup Financials
| BBIXF Stock | USD 0.02 0.00 0.00% |
Bonus |
Understanding current and past Bonus BioGroup Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bonus BioGroup's financial statements are interrelated, with each one affecting the others. For example, an increase in Bonus BioGroup's assets may result in an increase in income on the income statement.
Bonus BioGroup Stock Summary
Bonus BioGroup competes with Sino Biopharmaceutica, Defence Therapeutics, Aileron Therapeutics, and Enlivex Therapeutics. Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel. Bonus Biogroup is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Matam Advanced Technology |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.bonusbiogroup.com |
| Phone | 972 7 320 67104 |
| Currency | USD - US Dollar |
Bonus BioGroup Key Financial Ratios
There are many critical financial ratios that Bonus BioGroup's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Bonus BioGroup reports annually and quarterly.| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Beta | 1.4 |
Bonus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bonus BioGroup's current stock value. Our valuation model uses many indicators to compare Bonus BioGroup value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bonus BioGroup competition to find correlations between indicators driving Bonus BioGroup's intrinsic value. More Info.Bonus BioGroup is rated fifth in return on equity category among its peers. It is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bonus BioGroup's earnings, one of the primary drivers of an investment's value.Bonus BioGroup Systematic Risk
Bonus BioGroup's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bonus BioGroup volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-two with a total number of output elements of nineteen. The Beta measures systematic risk based on how returns on Bonus BioGroup correlated with the market. If Beta is less than 0 Bonus BioGroup generally moves in the opposite direction as compared to the market. If Bonus BioGroup Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bonus BioGroup is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bonus BioGroup is generally in the same direction as the market. If Beta > 1 Bonus BioGroup moves generally in the same direction as, but more than the movement of the benchmark.
Bonus BioGroup December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bonus BioGroup help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bonus BioGroup. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bonus BioGroup based on widely used predictive technical indicators. In general, we focus on analyzing Bonus Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bonus BioGroup's daily price indicators and compare them against related drivers.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 53.33 |
Complementary Tools for Bonus Pink Sheet analysis
When running Bonus BioGroup's price analysis, check to measure Bonus BioGroup's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bonus BioGroup is operating at the current time. Most of Bonus BioGroup's value examination focuses on studying past and present price action to predict the probability of Bonus BioGroup's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bonus BioGroup's price. Additionally, you may evaluate how the addition of Bonus BioGroup to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |